Skip to main content
AMPH
NASDAQ Life Sciences

Amphastar 10-Q: Q3 Revenue Up 8% to $207.6M, EPS $0.87, Gross Margin Slips to 48.0%

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$30.1
Mkt Cap
$1.177B
52W Low
$16.645
52W High
$29.52
52W Position info
81% above low
Off High info
at 52W high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

AMPH sits 81% above its 52-week low of $16.645.

Summary

Amphastar's Q3 10-Q confirms 8% revenue growth to $207.6M and $0.87 diluted EPS, but gross margin compressed to 48.0% on weaker pricing and IMS remediation costs, with a $12.5M IMS-related backlog disclosed.


Key Events · Earnings and Guidance · AMPH

  • Q3 Revenue Up 8% to $207.6M

    Net revenues rose to $207.6M from $191.8M, led by BAQSIMI at $58.8M (up 10%) and Primatene MIST at $31.5M (up 9%); lidocaine jumped 29% to $16.6M while glucagon fell 37% to $8.6M.

  • EPS Nearly Doubles, Margin Compresses

    Diluted EPS was $0.87 versus $0.37, helped by a $23.1M litigation provision in the prior-year quarter; gross margin fell to 48.0% from 51.4% on lower average selling prices for BAQSIMI, glucagon and epinephrine multi-dose vials plus higher IMS remediation and facility expansion costs.

  • IMS Warning Letter Creates $12.5M Backlog

    Slower product releases during FDA warning-letter remediation at the IMS facility left roughly $12.5M of backlog at September 30, 2026, and management expects manufacturing expenses to keep rising as remediation continues.

  • $100M Lilly Milestone Paid and Capitalized

    BAQSIMI's first annual net sales milestone of $175.0M triggered a $100.0M payment to Lilly in Q3, allocated $94.5M to product rights and $5.5M to PP&E and amortized over a 21-year remaining life.


Analysis · AMPH · Life Sciences

The full quarterly report behind this morning's headline reveals the quality of the beat: revenue growth is real, but gross margin fell to 48.0% from 51.4% as BAQSIMI, glucagon and epinephrine multi-dose vials sold at lower average prices, while IMS remediation and facility expansion raised manufacturing costs. The IMS FDA warning letter is now quantified — a $12.5M product backlog at quarter-end from slower releases — and management says manufacturing expense will keep rising as it remediates. Offsetting that, the $100.0M Lilly milestone for hitting BAQSIMI's first annual net sales threshold was paid in Q3 and capitalized ($94.5M to intangibles), so it hits the balance sheet and future amortization rather than the income statement. Cash stands at $204.6M against $620.4M of debt, and buybacks slowed sharply to 21,747 shares for $0.4M in Q3 versus $74.6M across the first nine months.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AMPH was trading at $30.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $16.65 to $29.52. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AMPH - Latest Insights

AMPH
Nov 05, 2026, 4:26 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $30.10
Real-time Price: $28.25 info
Change: -$1.85 (-6%) info
Market Cap: $1.205B info
AMPH
Nov 05, 2026, 4:10 PM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $27.66
Real-time Price: $28.25 info
Change: +$0.590 (+2%) info
Market Cap: $1.205B info
AMPH
Aug 06, 2026, 4:50 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $20.35
Real-time Price: $28.25 info
Change: +$7.90 (+39%) info
Market Cap: $1.205B info
AMPH
Aug 06, 2026, 4:05 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $20.35
Real-time Price: $28.25 info
Change: +$7.90 (+39%) info
Market Cap: $1.205B info
AMPH
Jul 13, 2026, 7:20 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $18.72
Real-time Price: $28.25 info
Change: +$9.53 (+51%) info
Market Cap: $1.205B info